‘Lee Cronin’s The Mummy’ is no match for ‘Super Mario’ or ‘Hail Mary’ at the box office

North American box office remained strong, led by "The Super Mario Galaxy Movie" at $35 million and "Project Hail Mary" at $20.5 million, while the new wide release "Lee Cronin’s The Mummy" opened third with $13.5 million. "Project Hail Mary" has reached $573.1 million worldwide and "Mario" $747.5 million worldwide, highlighting continued theatrical demand and solid IMAX support. The article also flags upcoming tracking for Lionsgate’s "Michael," which could open above $60 million and potentially set a record for a musical biopic.

Analysis

The key takeaway is not the weekend gross itself, but the evidence that premium-format demand is still the marginal driver of box office outperformance. IMAX screens remain a scarce asset, and the rotation back to a holdover with durable legs suggests theaters will keep optimizing for title mix rather than first-weekend novelty. That supports a longer-than-expected revenue runway for large-format exhibitors and screening-tech vendors if they can keep premium bookings elevated through the next 1-2 quarters.

The disappointment in the horror debut matters more as a signal than as an absolute dollar figure. The market may be overestimating the near-term elasticity of genre demand after a strong prior year: weak audience scores and poor critical reception imply that low-budget horror is still viable, but the win rate is thinning, which could pressure greenlighting discipline at studios and reduce content velocity for suppliers tied to volume rather than hits. In practical terms, that shifts bargaining power toward exhibitors with premium inventory and away from lower-tier releases competing for screens.

The bigger swing factor is the upcoming biopic launch, which can either validate a broad reacceleration in theatrical attendance or expose how concentrated demand remains in eventized titles. If that film clears the high end of tracking, it should reinforce the thesis that consumers will show up for culturally resonant, music-led IP and premium formats; if it misses, the market will likely re-rate the current box office recovery as franchise-dependent rather than cyclical. For SCOR, the read-through is more neutral: a healthy theatrical slate helps sentiment around media demand, but the real equity upside is likely in companies with leverage to premium-format utilization rather than the aggregate box office level.

Key Decisions for Investors

• Long IMAX into the next 2-6 weeks as a premium-format utilization play; risk/reward skews favorably if the upcoming release slate keeps IMAX allocation tight. Trim on any evidence of screen underutilization or if the next event title fails to clear tracking by 15%+.
• Use a pair trade: long IMAX / short a broad media-exhibition basket for 1-3 months to isolate premium-format share gains from the rest of theatrical normalization. The thesis is that premium screens capture disproportionate pricing power even if total box office stays range-bound.
• Avoid chasing SCOR on this print; use it only as a sentiment proxy until there is evidence of sustained box office acceleration beyond one or two event films. Upside is indirect and likely capped unless the market revises multi-quarter media demand assumptions upward.
• If the musical biopic opens above $60M domestic, add to IMAX on strength for a 1-2 week momentum trade. If it opens below $50M, fade the move via a short-term reversal trade, since the market will likely question whether premium attendance is broadening or just title-specific.